is metformin a glp-1 medication New aspects of an old drug: as glucagon-like peptide 1 (GLP-1) enhancer and sensitiser | Diabetologia Comparing Glucagon‐like peptide‐1 receptor agonists

While nausea can be uncomfortable, fewer than 10% of people in clinical trials stopped their medication because of gastrointestinal issues

The potential of the tri-agonist and the dual incretin GLP-1/GIP coagonist to antagonise the manifestation of spontaneous diabetes was examined in mouse models of T2D

This comprehensive analysis confirmed substantial reductions in hepatic fat content measured by MRI-PDFF (weighted mean difference -5.8%, 95%CI: -7.1% to -4.5%), liver enzymes, and histological parameters including steatosis and inflammation scores

Research on the potential for Ozempic to increase the risk of thyroid cancer is ongoing

Management of hyperglycemia in type 2 diabetes, 2022

Specifically, it has been established that 50% to 70% of insulin secretion in response to oral glucose administration is due to the incretin effect [1]